Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era?

Jagadeesh Bayry, Sébastien Lacroix-Desmazes, Michel D. Kazatchkine, Srini V. Kaveri

Forskningsoutput: TidskriftsbidragArtikel

72 Citeringar (Scopus)

Sammanfattning

The dramatic increase in both the number of novel infectious agents and resistance to antimicrobial drugs has incited the need for adjunct therapies in the war against infectious diseases. Exciting recent studies have demonstrated the use of antibodies in the form of intravenous immunoglobulin (IVIg) against infections. By virtue of the diverse repertoire of immunoglobulins that possess a wide spectrum of antibacterial and antiviral specificities, IVIg provides antimicrobial efficacy independently of pathogen resistance and represents a promising alternative strategy for the treatment of diseases for which a specific therapy is not yet available.
OriginalspråkEngelska
TidskriftTrends in Pharmacological Sciences
Volym25
Utgåva6
DOI
StatusPublicerad - 1 jan 2004

Fingeravtryck Fördjupa i forskningsämnen för ”Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era?”. Tillsammans bildar de ett unikt fingeravtryck.

  • Citera det här